Table S4.

Comparison of in vivo PMRs in individuals with positive or negative IgG responses to P. falciparum antigens alone or in combination

Univariate, Wilcoxon testLogistic regression
Negative respondersPositive respondersP valueP value
CombinationSample sizeMedian PMR (IQR)Sample sizeMedian PMR (IQR)UnadjustedBH-adjustedCoefficientUnadjustedBH-adjusted
PfMSRP5 + PfRh51972.92 (0.851–4.32)181.5 (0.501–2.96)0.02880.3094−0.81170.16090.9584
PfRAMA1832.92 (0.853–4.31)332.11 (0.589–3.01)0.03730.3094−0.49610.29050.9584
PfMSRP5 + PfSERA9 + PfRh52052.86 (0.851–4.29)100.696 (0.474–2.96)0.0650.3094−0.69540.34850.9584
PfMSRP5 + PfRAMA1932.91 (0.85–4.31)232.11 (0.595–2.97)0.07190.3094−0.39570.47190.9584
PfSERA9 + PfRh51932.91 (0.851–4.31)221.05 (0.619–3.09)0.07250.3094−0.47660.33480.9584
PfRh51722.93 (0.86–4.35)402.17 (0.646–3.64)0.07530.3094−0.32430.38910.9584
PfSERA91153 (0.779–4.43)1012.55 (0.785–3.74)0.08670.3094−0.41280.16550.9584
PfRAMA + PfRh52052.86 (0.851–4.29)100.696 (0.501–2.96)0.09120.3094−0.49590.51660.9584
PfMSRP5 + PfRAMA + PfRh52062.85 (0.851–4.28)100.696 (0.501–2.96)0.09270.3094−0.51120.50350.9584
PfEBA181 + PfRAMA1882.88 (0.851–4.3)282.1 (0.572–3.26)0.09670.3094−0.26690.58740.9584
PfEBA181 + PfMSRP5 + PfRh52032.86 (0.84–4.3)132.21 (0.52–3.01)0.1120.3258−0.67470.30380.9584
PfMSRP51572.96 (0.85–4.38)592.45 (0.776–3.53)0.140.3349−0.1830.59750.9584
PfEBA181 + PfMSRP5 + PfRAMA1962.85 (0.845–4.3)202.19 (0.632–3.12)0.1470.3349−0.046260.93610.9584
PfCyRPA2102.78 (0.758–4.15)64.23 (3.12–4.46)0.1510.33490.93620.330.9584
PfEBA181 + PfMSRP5 + PfSERA9 + PfRh52072.84 (0.84–4.27)90.723 (0.52–3.01)0.1570.3349−0.47430.53470.9584
PfEBA181 + PfMSRP5 + PfRAMA + PfRh52072.84 (0.84–4.27)90.723 (0.52–3.01)0.1840.3464−0.42650.58580.9584
PfEBA181 + PfRAMA + PfRh52072.84 (0.84–4.27)90.723 (0.52–3.01)0.1840.3464−0.42650.58580.9584
PfEBA1811013.04 (0.673–4.59)1152.67 (0.84–3.7)0.1960.3484−0.34560.28230.9584
PfEBA181 + PfRh51922.85 (0.82–4.32)242.23 (0.678–3.25)0.2270.3648−0.29320.52750.9584
PfMSRP5 + PfSERA91812.86 (0.85–4.29)352.65 (0.595–4.04)0.2280.3648−0.081070.84410.9584
PfEBA181 + PfSERA9 + PfRh51992.84 (0.81–4.3)172.12 (0.681–3.12)0.2860.3815−0.23810.66160.9584
PfEBA181 + PfRAMA + PfSERA91922.85 (0.82–4.26)242.3 (0.632–3.6)0.290.3815−0.070250.88930.9584
PfRAMA + PfSERA91922.85 (0.82–4.26)242.3 (0.632–3.6)0.290.3815−0.070250.88930.9584
PfEBA181 + PfMSRP511732.91 (0.756–4.34)432.75 (0.789–3.39)0.3030.3815−0.020430.95840.9584
PfEBA181 + PfMSRP5 + PfRAMA + PfSERA91992.84 (0.81–4.27)172.45 (0.669–3.44)0.310.38150.052370.93010.9584
PfMSRP5 + PfRAMA + PfSERA91992.84 (0.81–4.27)172.45 (0.669–3.44)0.310.38150.052370.93010.9584
PfEBA181 + PfMSRP5 + PfRAMA + PfSERA9 + PfRh52082.83 (0.82–4.26)81.76 (0.632–3.27)0.370.3947−0.2270.77580.9584
PfEBA181 + PfRAMA + PfSERA9 + PfRh52082.83 (0.82–4.26)81.76 (0.632–3.27)0.370.3947−0.2270.77580.9584
PfMSRP5 + PfRAMA + PfSERA9 + PfRh52082.83 (0.82–4.26)81.76 (0.632–3.27)0.370.3947−0.2270.77580.9584
PfRAMA + PfSERA9 + PfRh52082.83 (0.82–4.26)81.76 (0.632–3.27)0.370.3947−0.2270.77580.9584
PfEBA181 + PfMSRP5 +Pf SERA91862.85 (0.801–4.28)302.73 (0.738–3.86)0.3910.4036−0.032990.94080.9584
PfEBA181 + PfSERA91382.89 (0.692–4.31)782.73 (0.866–3.98)0.7130.713−0.15370.63170.9584
  • Details of the analyses are described in SI Methods. BH, Benjamini–Hochberg; IQR, interquartile range; PMR, parasite multiplication rate. Bold rows indicate statistical significance in the univariate analysis (unadjusted P value < 0.05).